In recent years, laboratory discoveries have led to the development of new drugs designed to target and attack cancer cells, leaving healthy ones intact. One key weapon in this arsenal of new therapies is called Herceptin, a drug that is currently used to treat breast cancer and works by targeting a specific protein that controls cell growth called HER-2/neu. But despite the drugs effectiveness, tumors shrink in only the small percentage of breast cancer patients whose cancer cells express an over-abundance of HER-2/neu.
Now, laboratory studies conducted by researchers at Cedars-Sinai Medical Center and Genentech have found that a potent experimental drug called 2C4 slows tumor growth in both breast and prostate cancer tumors in mice even when small amounts of HER-2/neu are expressed. The findings appear in the August issue of the journal, Cancer Cell, and may lead to a new way to treat breast and prostate cancers and other solid tumors.
"We found that 2C4 not only targeted HER-2/neu, but that it disrupted cell signaling among the entire HER family of proteins," said Dr. David Agus, Research Director at the Cedars-Sinai Prostate Cancer Center and first author of the study. "As a result of these lab studies, clinical trials are currently underway to test the safety and effectiveness of 2C4 in patients with breast and prostate cancer, as well as other solid tumors."
The drug, called 2C4, is a monoclonal antibody, or molecule that enlists the bodys immune system to attack foreign invaders, such as viruses or bacteria. Produced by Genentech, Inc., 2C4 is similar to Herceptin in that it targets HER-2/neu, a member of the HER kinase family of proteins. The protein sits on the surface of cancer cells and receives signals from "growth factor" molecules within the HER family, which, in turn, stimulate tumors to grow.
Kelli Stauning | EurekAlert!
Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg
New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences